Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer
Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of BKM120 in combination with trastuzumab in
patients with relapsing HER2 overexpressing breast cancer who have previously failed
trastuzumab.
The study will further assess the safety and preliminary efficacy of BKM120 in combination
with trastuzumab and capecitabine in patients with relapsing HER2 overexpressing breast
cancer and brain metastases (BM) who have previously failed trastuzumab.